Get started
VYNE Therapeutics Inc.VYNE Therapeutics Inc.VYNE Therapeutics Inc.

VYNE Therapeutics Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

VYNE trade ideas

VYNE, going upward after a congestion areaAfter a downward breakout on the support, the price went to the lowest lower of 1.67. However, buyers went strong and rise the price. During almost 1 month, the price was in a congestion area, and sellers try again to break the support, and they failed with strongers buyers, making a three white soldiers, and crossing the congestion area. This area was crossed and ended with a doji, and a day after the price opened above almost 5%. We can see the strenght of ADX increasing as well as DMI+, and the opposite for DMI- that is decreasing. We can also see that after the breakout, the price comes again to a 10-EMA, that was the top of the congestion area. The volume increased a lot during the breakout of the congestion area.
NASDAQ:VYNELong
by AFCapital21
VYNE Biotech Post Earnings VYNE had a favorable earnings report last week. Fundamentally, analysts predict ( linked) approximately a doubling of the shart price in the next year. Like many low share priced biotechnology stocks the price is based on perceived future earnings which can be affected by favorable FDA process, or well-received research at industry conferences and changing financials within the company. In general, they have a low beta meaning these stocks are not general market responsive and run on their own present or future merits. On the 15-minute chart VYNE was trending down into earnings and the pivoted with a reversal into the present. The Luxalgo AI "Echo indicator" predicts an upside of 20% in the next two days before a consolidation period. The "Trendflex" indicator has flipped to postiive and green. I will take this long trade with a stop loss of $0.15 per share and target of $9.00 over two days for a 20% ROI and a R:R of 0.15 risk / $ 1.50 reward for a 10:1> Iwill only take biotechology trades long with a high R:R due to the inheret risk level.
NASDAQ:VYNE
by AwesomeAvani
LONG Sec.gov Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. The Company commenced capitalizing inventory for AMZEEQ and ZILXI upon FDA approval in October 2019 and May 2020, respectively. The Company periodically reviews its inventory levels and, if necessary, writes down inventory that is expected to expire prior to being sold, inventory in excess of expected sales requirements, and inventory that fails to meet commercial sale specifications, with a corresponding charge to cost of goods sold. There were no material write-downs during the three and nine months ended September 30, 2021, and September 30, 2020. The Company evaluated the realizability of inventory giving consideration to the strategic business review discussed in Note 1 and no impairment charges resulted from this review as of September 30, 2021. The Company will continue to evaluate the realizability of its inventory during the process to explore a possible sale or license of its topical minocycline franchise. The following table sets forth the Company’s inventory: September 30, 2021 December 31, 2020 (in thousands) Raw materials $3,247 $4,042 Work-in-process $339 $662 Finished goods $4,484 $2,700 Total $8,070 $7,404
NASDAQ:VYNELong
by Susan1979
$VYNE Support and ResistanceHC Wainwright & Co. Assumes VYNE Therapeutics at Buy, Announces Price Target of $7 VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
NASDAQ:VYNELong
by BADQOMOCAWGOWLD
My long-term goal on VYNE Since VYNE Therapeutics has enough cash (148m) for 2021 and even into 2022 (possible to turn profitable in 2021), they have a stable cash burn rate. Indicates their financials are strong. Break-even reaches 8500 prescriptions a week / 25 million quarter. Furthermore, with two approved FDA drugs commercialized (AMZEEQ and ZILXI covered by three major PBMS, coverage ahead of schedule ) were AMZEEQ's regular price ($200-$250) will kick in by Q2 and Q3 (due to covid-19). According to today's knowledge, there is no insider selling—instead, insiders buy-in (Perceptive, Blackrock, own BOD, and management team buy). On-going product pipeline: FMX114 recently announced a Multi-modal approach, and the intention is to diversify the pipeline. Phase 2 is covered by the budget. FCD105 was going through Phase 2A. FCD Approval expected End 2023/beginning 2024, and phase 3 will start end of this year. Budget coverage is expected. Since the reverse split - lowered float from 252 million to 51 million shares outstanding. VYNE has seven buy ratings with an average target of $20,86, a high target of $40 / a low target of $12. I am confident we will see a closer trading price near $20 rather than $10 EOY 21. This is not financial advice.
NASDAQ:VYNELong
by Lovelyfluffybeard
5
VYNE: Entering at a support after reverse stock splitVYNE Therapeutics Inc. has caught my attention recently after they announced a reverse stock split at a ratio of 1-for-4. As a novice trader, I am now interested in observing this stock's behavior as it starts trading on a split-adjusted basis, apparently on February 16th. Consequently, I have opened a position with the belief that the price will see an uptrend. I do not believe stock splits change fundamentals, but there are good reasons to believe that decreased liquidity of stocks may increase the price in the near future. The primary objective of the reverse stock split is to reduce the number of shares outstanding to a number more consistent with other companies with similar market capitalizations as VYNE, as further described in the Company’s last proxy statement (GlobeNewswire). Technical Indicators (1h) Strong support seems to be forming around 2.50 Seems too low volume to justify the current down trend Looking at oversold signals from RSI near support (highlighted in orange) Looking at the MACD for a crossover (highlighted in orange) I have orders set for half my position at 2.65 and half at 2.50 if price drops to that support; I think entering in that range is acceptable. Please feel free to comment on my analysis. Despite having traded for a while, I am fairly new at technical analysis and would love to learn from experienced people in this community.
NASDAQ:VYNELong
by feelsgains
6
My long term thougt of VYNEI recently discovered VYNE - Not sure how, but what made me interested in investing in this stock was their potential to help individuals with severe acne, and based on the technical aspect of bottom formed curve and "break out" from its consolidation period, I felt it was a good thought to get into this company. It might actually become my future pension fund. However, you shall never fall in love with a stock. The technical aspect appears like vyne has entered a rising price channel towards $3.75 and $4.98. Yet, it much depends on what momentum we are going to have. A fallback to $2.60 is much possible, even $1.97. I am in for the long run - I will add and strengthening my position once I have a chance to do so. In 2-3 years, I have high hopes to see at least $11.80. /Fluff ----------------------------------------- Disclaimer: This is my thoughts and not a recommendation to buy/sell the mentioned stock. Do your own DD analysis. I am not a professional stock trader.
NASDAQ:VYNELong
by Lovelyfluffybeard
VYNE - upTrend is underwayVYNE gapped strongly on 25th January, breaking out of a 10-month resistence @ 2.68 but alas failed to hold on to this level as it then gave up all the gains over the next 1 week to close the gap before attempting to reverse up again. It finally broke and CLOSED above this 2.68 resistence (now turned support) on 3rd Feb, retesting this new support over the next few days before springboarding off decisively today with a huge green candle, signalling that it's uptrend is now underway! :D Initial stop loss just below 2.68 (trail stops up with at least 12%-15% wiggle room on the way up). Expect to see some consolidation each time the stock hits into some old "resistences" on the way up. Disclaimer: This is just my own analysis and opinion for discussion and is not a trade advice. Kindly do your own due diligence and trade according to your own risk tolerance. Thank you. Feel free to let me have your thoughts ! :)
NASDAQ:VYNELong
by Juliac
12